Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Inks Agreement with MultiPlan for Access to Breast Cancer Tests

NEW YORK (GenomeWeb News) – Genetic test development firm Atossa Genetics, which is waiting to complete its initial public offering, disclosed last week an agreement to provide access to its tests to providers and patients in managed healthcare plan MultiPlan's networks.

Under the terms of the deal, disclosed in a document filed with the US Securities and Exchange Commission, providers and patients in MultiPlan, PHCS, and PHCS Savility Networks will be able to access Atossa's tests, including the ForeCYTE and ArgusCYTE Breast Health Tests. Additional details of the deal were not disclosed.

ForeCYTE, based on Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT, provides information about the 10-year and lifetime risk of breast cancer for women between 18 and 65 years old.

ArgusCYTE helps guide treatment for breast cancer and monitors potential recurrence.

MultiPlan is a national managed health care preferred provider organization headquartered in New York. About 900,000 healthcare providers participate in its provider networks and 57 million patients have access to one or more of the networks, it said.

In the SEC document, Seattle-based Atossa also disclosed that as of Aug. 31 it had $7,631 in cash and cash equivalents and $250,000 in restricted cash.

Atossa refiled for an IPO earlier this year. Last month, it lowered the expected share price for its offering to a range of $4 to $6 from an earlier range of $5 to $7.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.